Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem.
about
Three decades of beta-lactamase inhibitorsInfections Caused by Acinetobacter baumannii in Recipients of Hematopoietic Stem Cell Transplantation.Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England.Acinetobacter baumannii: emergence of a successful pathogenTreatment of Acinetobacter spp infections.Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomyPopulation pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment.Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii.Antibacterial susceptibility patterns and cross-resistance of acinetobacter, isolated from hospitalized patients, southern iran.Nosocomial bacterial infections in Intensive Care Units. I: Organisms and mechanisms of antibiotic resistance.Characterization and distribution of drug resistance associated β-lactamase, membrane porin and efflux pump genes in MDR A. baumannii isolated from Zhenjiang, ChinaOptimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaComparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia.Treatment options for multidrug-resistant bacteria.Dissemination of a clone of unusual phenotype of pandrug-resistant Acinetobacter baumannii at a university hospital in Taiwan.Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections.In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.Active efflux pump adeB is involved in multidrug resistance of Acinetobacter baumannii induced by antibacterial agents.Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review.In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.Molecular and epidemiologic study of polyclonal outbreaks of multidrug-resistant Acinetobacter baumannii infection in an Israeli hospital.Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods.Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.Multidrug-resistant Acinetobacter baumannii outbreak in an intensive care unit.Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study.Molecular epidemiology and mechanism of sulbactam resistance in Acinetobacter baumannii isolates with diverse genetic background in China.Concurrent outbreak of multidrug-resistant and susceptible subclones of Acinetobacter baumannii affecting different wards of a single hospital.Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells
P2860
Q24646623-BAD8FC28-C3F9-460C-8CCB-795202483F51Q33892585-9EEE8AF6-6AC8-4B77-845F-0D76001F6789Q34571574-444F40C4-E751-42FA-9177-0C285C9CB04DQ34795807-A1F7177F-8558-486B-AF48-2C0BB04B27AEQ35183740-24604E48-01A4-4854-B654-A61A3FAA717CQ35205195-46154FA2-E74A-4E22-AA9A-FBFD383CD6DFQ35211425-5F686E0D-6685-4A47-85E0-BBC74B59293AQ35784520-C960AEC9-EBC4-4738-B3AF-02C0C4C782A9Q36022229-075C78A2-867A-4D81-9051-B9B41DE6B16CQ36237707-CF7FDA4A-C488-4301-953C-C13A6B2102DEQ36317521-79E61802-A426-4C91-93E3-B82D0460A93AQ36363261-FA2934E6-564C-480D-ABC5-5B39D76D211BQ36406755-9A37C1D9-EFBB-4F5D-ABE4-8F592E2654D4Q36607401-84701D3E-6DF7-4D35-8560-F197F549D359Q37420672-3F3BCEF6-C153-4FD5-964C-F7706F92E6F9Q37557606-24E21032-28EA-461B-884B-384F6D3D054AQ37733474-EFB9536E-C8A9-42AA-93DC-7DEE942AC5F9Q37734987-75DD5D89-811F-476E-8ED6-B65AD4D1DC78Q38212031-9F2EC5FC-BB43-4CBC-8106-2913ADC4BF24Q39677063-E0E1F3D3-68A2-4532-A19D-405227409B5DQ40196177-B156E7DA-F517-4C66-B4F8-DC496E77C15AQ40282151-5593D056-F2A7-4C82-BC06-90C7768DBC60Q41561999-B64CE59F-5861-48CF-AD1F-7840CCEADEB3Q42239726-105C02D3-7163-4DEB-8B5B-1F5A2C0C73BCQ44032743-E81D0D51-917D-4CD4-B824-FDDE8F481F72Q46929397-41E5A30F-2A44-4C74-A78A-29991DEA4E25Q50134154-1E3C034C-6C41-4D5F-AAAC-AB990A477E12Q53871945-905CCAF0-7A43-4CC7-B710-397E3C6A2AD2Q58765247-1D5DF883-207C-4020-9037-9D73334BE9BB
P2860
Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Multiresistant Acinetobacter i ...... an emerging worldwide problem.
@ast
Multiresistant Acinetobacter i ...... an emerging worldwide problem.
@en
Multiresistant Acinetobacter i ...... an emerging worldwide problem.
@nl
type
label
Multiresistant Acinetobacter i ...... an emerging worldwide problem.
@ast
Multiresistant Acinetobacter i ...... an emerging worldwide problem.
@en
Multiresistant Acinetobacter i ...... an emerging worldwide problem.
@nl
prefLabel
Multiresistant Acinetobacter i ...... an emerging worldwide problem.
@ast
Multiresistant Acinetobacter i ...... an emerging worldwide problem.
@en
Multiresistant Acinetobacter i ...... an emerging worldwide problem.
@nl
P1476
Multiresistant Acinetobacter i ...... an emerging worldwide problem.
@en
P2093
P304
P356
10.1046/J.1469-0691.2002.00415.X
P577
2002-03-01T00:00:00Z